- Home
- BLTE vs WGS Comparison
BLTE vs WGS Comparison
Compare BLTE & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- WGS
- Stock Information
- Founded
- BLTE 2018
- WGS 2017
- Country
- BLTE United States
- WGS United States
- Employees
- BLTE N/A
- WGS N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- BLTE Health Care
- WGS Technology
- Exchange
- BLTE Nasdaq
- WGS Nasdaq
- Market Cap
- BLTE 2.1B
- WGS 2.4B
- IPO Year
- BLTE 2022
- WGS N/A
- Fundamental
- Price
- BLTE $65.74
- WGS $132.54
- Analyst Decision
- BLTE Strong Buy
- WGS Strong Buy
- Analyst Count
- BLTE 4
- WGS 7
- Target Price
- BLTE $96.67
- WGS $99.29
- AVG Volume (30 Days)
- BLTE 39.8K
- WGS 666.9K
- Earning Date
- BLTE 08-11-2025
- WGS 10-28-2025
- Dividend Yield
- BLTE N/A
- WGS N/A
- EPS Growth
- BLTE N/A
- WGS N/A
- EPS
- BLTE N/A
- WGS 0.05
- Revenue
- BLTE N/A
- WGS $362,321,000.00
- Revenue This Year
- BLTE N/A
- WGS $35.84
- Revenue Next Year
- BLTE N/A
- WGS $18.46
- P/E Ratio
- BLTE N/A
- WGS $2,732.19
- Revenue Growth
- BLTE N/A
- WGS 48.70
- 52 Week Low
- BLTE $43.70
- WGS $28.86
- 52 Week High
- BLTE $86.53
- WGS $134.43
- Technical
- Relative Strength Index (RSI)
- BLTE 52.03
- WGS 70.44
- Support Level
- BLTE $62.18
- WGS $125.00
- Resistance Level
- BLTE $66.15
- WGS $134.43
- Average True Range (ATR)
- BLTE 2.66
- WGS 5.80
- MACD
- BLTE -0.16
- WGS -0.57
- Stochastic Oscillator
- BLTE 72.80
- WGS 90.63
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.